Medpace Holdings Inc (MEDP) FinancialsMEDPMedpace Holdings Inc

Medpace Holdings, Inc. (MEDP) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Metabolic, accounting for 31.0% of total sales, equivalent to $219.07M. Other significant revenue streams include Oncology and Other. Understanding this composition is critical for investors evaluating how MEDP navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Medpace Holdings, Inc. maintains a gross margin of 30.35%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 23.12%, while the net margin is 19.20%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively MEDP converts its operational activities into shareholder value.

In the context of the broader market, MEDP competes directly with industry leaders such as ROL and ULS. With a market capitalization of $18.49B, it holds a leading position in the sector. When comparing efficiency, MEDP's gross margin of 30.35% stands against ROL's 50.44% and ULS's 51.10%. Such benchmarking helps identify whether Medpace Holdings, Inc. is trading at a premium or discount relative to its financial performance.

Medpace reported a trailing twelve-month revenue of $2.8 billion and a net income of $491.5 million, reflecting strong demand for its services. The gross margin is currently at 27.56%, and the net margin is at 17.16%, indicating solid profitability.